| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From the Department of Pathology*and the Sidney Kimmel Comprehensive Cancer Center,The Johns Hopkins Medical Institutions, Baltimore, Maryland
Hepatocellular carcinoma (HCC) is one of the most fatal human malignancies, but the molecular mechanisms of hepatocarcinogenesis remain unclear. Although p53 mutations are frequently observed in Asian HCC, it is not a common event in Western HCC. Recent studies suggest that tumor suppressor genes (TSGs) can also be silenced through epigenetic disruption, such as promoter CpG island methylation, during carcinogenesis. To further understand the molecular mechanism of hepatocarcinogenesis, we have investigated the promoter methylation status of nine TSGs (SOCS-1, GSTP, APC, E-cadherin, RAR-ß, p14, p15, p16, and p73) in 51 cases of HCC using methylation-specific polymerase chain reaction. We found that 82% of HCCs had methylation of at least one TSG promoter. The most frequently methylated TSGs in HCC were: SOCS-1 (65%), GSTP (54%), APC (53%), E-cadherin (49%), and p15 (49%). Methylation of SOCS-1, GSTP, APC, E-cadherin, and p15 was more frequent in HCC than in nontumor liver (P < 0.05). Methylation of SOCS-1, GSTP, and p15 was also significantly more frequent in HCC than cirrhotic liver (P < 0.05). Although methylation of one or two genes could be seen in both nontumor and cirrhotic livers, 53% of the HCC cases had three or more TSG promoters methylated, in comparison to 0% in nontumor liver and 13% in cirrhosis (P = 0.001). Methylation of SOCS-1, APC, and p15 was more frequently seen in hepatitis C virus-positive HCC than hepatitis C virus/hepatitis B virus-negative HCC. Our data suggest that promoter hypermethylation of TSGs is a common event in HCC and may play an important role in hepatocarcinogenesis.
This article has been cited by other articles:
 |
|
 |
|
  I Tischoff, U R Hengge, M Vieth, C Ell, M Stolte, A Weber, W E Schmidt, and A Tannapfel Methylation of SOCS-3 and SOCS-1 in the carcinogenesis of Barrett's adenocarcinoma Gut, August 1, 2007; 56(8): 1047 - 1053. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. K. Jung, P. Arora, J. S. Pagano, and K. L. Jang Expression of DNA Methyltransferase 1 Is Activated by Hepatitis B Virus X Protein via a Regulatory Circuit Involving the p16INK4a-Cyclin D1-CDK 4/6-pRb-E2F1 Pathway Cancer Res., June 15, 2007; 67(12): 5771 - 5778. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Nishida, T. Nishimura, T. Nagasaka, I. Ikai, G. Ajay, and C. R. Boland Extensive Methylation Is Associated with {beta}-Catenin Mutations in Hepatocellular Carcinoma: Evidence for Two Distinct Pathways of Human Hepatocarcinogenesis Cancer Res., May 15, 2007; 67(10): 4586 - 4594. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Epstein and T. W. Leung Reversing Hepatocellular Carcinoma Progression by Using Networked Biological Therapies Clin. Cancer Res., January 1, 2007; 13(1): 11 - 17. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Yuan, J. Wang, J. Li, L. Wang, M. Li, Z. Yang, C. Zhang, and J. L. Dai Frequent Epigenetic Inactivation of Spleen Tyrosine Kinase Gene in Human Hepatocellular Carcinoma. Clin. Cancer Res., November 15, 2006; 12(22): 6687 - 6695. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H. Wei, C. Balch, H. H. Paik, Y.-S. Kim, R. L. Baldwin, S. Liyanarachchi, L. Li, Z. Wang, J. C. Wan, R. V. Davuluri, et al. Prognostic DNA methylation biomarkers in ovarian cancer. Clin. Cancer Res., May 1, 2006; 12(9): 2788 - 2794. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Katoh, T. Shibata, A. Kokubu, H. Ojima, M. Fukayama, Y. Kanai, and S. Hirohashi Epigenetic Instability and Chromosomal Instability in Hepatocellular Carcinoma Am. J. Pathol., April 1, 2006; 168(4): 1375 - 1384. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-H. Yeh, D.-C. Wu, C.-Y. Tsai, T.-J. Kuo, W.-C. Yu, Y.-S. Chang, C.-L. Chen, C.-F. Chang, D.-S. Chen, and P.-J. Chen Genetic Characterization of Fas-Associated Phosphatase-1 as a Putative Tumor Suppressor Gene on Chromosome 4q21.3 in Hepatocellular Carcinoma Clin. Cancer Res., February 15, 2006; 12(4): 1097 - 1108. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Hellerbrand, M. Muhlbauer, S. Wallner, M. Schuierer, I. Behrmann, F. Bataille, T. Weiss, J. Scholmerich, and A.-K. Bosserhoff Promoter-hypermethylation is causing functional relevant downregulation of methylthioadenosine phosphorylase (MTAP) expression in hepatocellular carcinoma Carcinogenesis, January 1, 2006; 27(1): 64 - 72. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. V. Brock, C. M. Hooker, R. Yung, M. Guo, Y. Han, S. E. Ames, D. Chang, S. C. Yang, D. Mason, M. Sussman, et al. Can We Improve the Cytologic Examination of Malignant Pleural Effusions Using Molecular Analysis? Ann. Thorac. Surg., October 1, 2005; 80(4): 1241 - 1247. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Liu, L.-E Wang, L. Wang, K. H. Lu, G. B. Mills, M. L. Bondy, and Q. Wei Methylation and Messenger RNA Expression of p15INK4b but Not p16INK4a Are Independent Risk Factors for Ovarian Cancer Clin. Cancer Res., July 1, 2005; 11(13): 4968 - 4976. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Lehmann, I. Berg-Ribbe, L. U. Wingen, K. Brakensiek, T. Becker, J. Klempnauer, B. Schlegelberger, H. Kreipe, and P. Flemming Distinct Methylation Patterns of Benign and Malignant Liver Tumors Revealed by Quantitative Methylation Profiling Clin. Cancer Res., May 15, 2005; 11(10): 3654 - 3660. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Ye, X. Li, X. Kong, W. Wang, Y. Bi, L. Hu, B. Cui, X. Li, and G. Ning Hypomethylation in the promoter region of POMC gene correlates with ectopic overexpression in thymic carcinoids J. Endocrinol., May 1, 2005; 185(2): 337 - 343. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Cerimele, T. Battle, R. Lynch, D. A. Frank, E. Murad, C. Cohen, N. Macaron, J. Sixbey, K. Smith, R. S. Watnick, et al. Reactive oxygen signaling and MAPK activation distinguish Epstein-Barr Virus (EBV)-positive versus EBV-negative Burkitt's lymphoma PNAS, January 4, 2005; 102(1): 175 - 179. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-J. Jeong, H.-J. Shin, S.-J. Kim, G.-H. Ha, B.-I. Cho, K.-H. Baek, C.-M. Kim, and C.-W. Lee Transcriptional Abnormality of the hsMAD2 Mitotic Checkpoint Gene Is a Potential Link to Hepatocellular Carcinogenesis Cancer Res., December 1, 2004; 64(23): 8666 - 8673. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Li, A.-M. Hui, L. Sun, K. Hasegawa, G. Torzilli, M. Minagawa, T. Takayama, and M. Makuuchi p16INK4A Hypermethylation Is Associated with Hepatitis Virus Infection, Age, and Gender in Hepatocellular Carcinoma Clin. Cancer Res., November 15, 2004; 10(22): 7484 - 7489. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Guo, M. G. House, C. Hooker, Y. Han, E. Heath, E. Gabrielson, S. C. Yang, S. B. Baylin, J. G. Herman, and M. V. Brock Promoter Hypermethylation of Resected Bronchial Margins: A Field Defect of Changes? Clin. Cancer Res., August 1, 2004; 10(15): 5131 - 5136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Reesink-Peters, G. B. A. Wisman, C. Jeronimo, C. Y. Tokumaru, Y. Cohen, S. M. Dong, H. G. Klip, H. J. Buikema, A. J.H. Suurmeijer, H. Hollema, et al. Detecting Cervical Cancer by Quantitative Promoter Hypermethylation Assay on Cervical Scrapings: A Feasibility Study Mol. Cancer Res., May 1, 2004; 2(5): 289 - 295. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
